Donald D Anthony1, Mark S Sulkowski2, Laura M Smeaton3, Sofi Damjanovska1, Carey L Shive1, Corinne M Kowal1, Daniel E Cohen4, Debika Bhattacharya5, Beverly L Alston-Smith6, Ashwin Balagopal2, David L Wyles7. 1. Departments of Medicine and Pathology, VA Medical Center and MetroHealth Medical Center, Case Western Reserve University, ACTG Immunology Support Laboratory, Cleveland Ohio, USA. 2. Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. 3. Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA. 4. AbbVie Inc, North Chicago, Illinois, USA. 5. Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA. 6. Division of AIDS, National Institutes of Health, Bethesda, Maryland, USA. 7. University of Colorado School of Medicine, Denver, Colorado, USA.
Abstract
BACKGROUND: Hepatitis C virus (HCV) direct-acting antivirals are highly effective. Less is known about changes in markers of immune activation in persons with human immunodeficiency virus (HIV) in whom a sustained virologic response (SVR) is achieved. METHODS: We conducted a nonrandomized clinical trial of 12 or 24 weeks of paritaprevir-ritonavir-ombitasvir plus dasabuvir (PrOD) with or without ribavirin in persons with HCV-1/HIV coinfection suppressed with antiretroviral therapy. Plasma HCV, soluble CD14 (sCD14), interferon-inducible protein 10, soluble CD163 (sCD163), interleukin 6 (IL-6), interleukin 18, monocyte chemoattractant protein (MCP-1), autotaxin (ATX), and Mac2-binding protein (Mac2BP) were measured over 48 weeks. RESULTS: Participants were treated with PrOD for 12 (n = 9) or 24 (n = 36) weeks; the SVR rate at 12 weeks was 93%. At baseline, cirrhosis was associated with higher ATX and MCP-1, female sex with higher ATX and IL-6, older age with higher Mac2BP, higher body mass index with higher ATX, and HIV-1 protease inhibitor use with higher sCD14 levels. In those with SVR, interferon-inducible protein 10, ATX, and Mac2BP levels declined by week 2, interleukin 18 levels declined by the end of treatment, sCD14 levels did not change, and sCD163, MCP-1, and IL-6 levels changed at a single time point. CONCLUSIONS: During HIV/HCV coinfection, plasma immune activation marker heterogeneity is in part attributable to age, sex, cirrhosis, body mass index, and/or type of antiretroviral therapy. HCV treatment with paritaprevir-ritonavir-ombitasvir plus dasabuvir is highly effective and is associated with variable rate and magnitude of decline in markers of immune activation. CLINICAL TRIALS REGISTRATION: NCT02194998. Published by Oxford University Press for the Infectious Diseases Society of America 2020.
BACKGROUND: Hepatitis C virus (HCV) direct-acting antivirals are highly effective. Less is known about changes in markers of immune activation in persons with human immunodeficiency virus (HIV) in whom a sustained virologic response (SVR) is achieved. METHODS: We conducted a nonrandomized clinical trial of 12 or 24 weeks of paritaprevir-ritonavir-ombitasvir plus dasabuvir (PrOD) with or without ribavirin in persons with HCV-1/HIV coinfection suppressed with antiretroviral therapy. Plasma HCV, soluble CD14 (sCD14), interferon-inducible protein 10, soluble CD163 (sCD163), interleukin 6 (IL-6), interleukin 18, monocyte chemoattractant protein (MCP-1), autotaxin (ATX), and Mac2-binding protein (Mac2BP) were measured over 48 weeks. RESULTS: Participants were treated with PrOD for 12 (n = 9) or 24 (n = 36) weeks; the SVR rate at 12 weeks was 93%. At baseline, cirrhosis was associated with higher ATX and MCP-1, female sex with higher ATX and IL-6, older age with higher Mac2BP, higher body mass index with higher ATX, and HIV-1 protease inhibitor use with higher sCD14 levels. In those with SVR, interferon-inducible protein 10, ATX, and Mac2BP levels declined by week 2, interleukin 18 levels declined by the end of treatment, sCD14 levels did not change, and sCD163, MCP-1, and IL-6 levels changed at a single time point. CONCLUSIONS: During HIV/HCV coinfection, plasma immune activation marker heterogeneity is in part attributable to age, sex, cirrhosis, body mass index, and/or type of antiretroviral therapy. HCV treatment with paritaprevir-ritonavir-ombitasvir plus dasabuvir is highly effective and is associated with variable rate and magnitude of decline in markers of immune activation. CLINICAL TRIALS REGISTRATION: NCT02194998. Published by Oxford University Press for the Infectious Diseases Society of America 2020.
Authors: Peter W Hunt; Elizabeth Sinclair; Benigno Rodriguez; Carey Shive; Brian Clagett; Nicholas Funderburg; Janet Robinson; Yong Huang; Lorrie Epling; Jeffrey N Martin; Steven G Deeks; Curtis L Meinert; Mark L Van Natta; Douglas A Jabs; Michael M Lederman Journal: J Infect Dis Date: 2014-04-21 Impact factor: 5.226
Authors: Rebecca T Veenhuis; Jacquie Astemborski; Michael A Chattergoon; Paige Greenwood; Marissa Jarosinski; Richard D Moore; Shruti H Mehta; Andrea L Cox Journal: Clin Infect Dis Date: 2016-12-07 Impact factor: 9.079
Authors: Jürgen K Rockstroh; Chloe Orkin; Rolando M Viani; David Wyles; Anne F Luetkemeyer; Adriano Lazzarin; Ruth Soto-Malave; Mark R Nelson; Sanjay R Bhagani; Hartwig H F Klinker; Giuliano Rizzardini; Pierre-Marie Girard; Cristina Tural; Nancy S Shulman; Niloufar Mobashery; Yiran B Hu; Linda M Fredrick; Tami Pilot-Matias; Roger Trinh; Edward Gane Journal: Open Forum Infect Dis Date: 2017-07-22 Impact factor: 3.835
Authors: Ann W N Auma; Carey Shive; Sofi Damjanovska; Corinne Kowal; Daniel E Cohen; Debika Bhattacharya; Beverly Alston-Smith; Melissa Osborne; Robert Kalayjian; Ashwin Balagopal; Mark Sulkowski; David Wyles; Donald D Anthony Journal: Open Forum Infect Dis Date: 2021-02-18 Impact factor: 4.423